Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer
← catalyst calendarNCT05634954 · readout ≤ 134 d
Sponsored by GE Healthcare (industry) · GEHC — their whole pipeline →. With Laboratory Corporation of America.
Phase
Phase 1
Status
Withdrawn
Study type
Interventional
Design
Non randomized · None · Diagnostic
Enrollment
0actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Business Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Feb 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Interventions
- Drug: GEH121224 (18F) Injection
- Diagnostic test: Dynamic and Static - PET/CT Scan
- Diagnostic test: Static - PET/CT Scan
Primary outcomes
what the primary-completion date above is the date OFSpecific absorbed dose to the target lesions, specific absorbed dose per organ, and total effective dose of [18F]GEH121224.
measured 6 months
Change in injection site status following administration of [18F]GEH121224
measured Before [18F]GEH121224 administration, immediately after dynamic whole body PET/CT scan and single whole body scans
Occurrence of Adverse Events (AEs) following administration of [18F]GEH121224
measured 6 months
Changes in heart rate as beats per minute following administration of [18F]GEH121224
measured Baseline, before [18F]GEH121224 administration, immediately after dynamic whole body PET/CT scan and single whole body scans
Changes in blood pressure in mmHg following administration of [18F]GEH121224
measured Baseline, before [18F]GEH121224 administration, immediately after dynamic whole body PET/CT scan and single whole body scans
Changes in temperature as degree C following administration of [18F]GEH121224
measured Baseline, before [18F]GEH121224 administration, immediately after dynamic whole body PET/CT scan and single whole body scans
Changes in respiration rate as breaths per minute following administration of [18F]GEH121224
measured Baseline, before [18F]GEH121224 administration, immediately after dynamic whole body PET/CT scan and single whole body scans
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of [18F]GEH121224
measured Baseline, before [18F]GEH121224 administration, immediately after single whole body PET/CT scans
Permalink · GEHC's whole pipeline · Catalyst calendar · Every registered study · What changed